Ardelyx - ARDX Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price targets for Ardelyx's stock. Their ARDX share price forecasts range from $1.00 to $10.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 174.7% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $1.10 at the beginning of the year. Since then, ARDX stock has increased by 65.5% and is now trading at $1.82.
View the best growth stocks for 2022 here.

Ardelyx saw a increase in short interest in November. As of November 15th, there was short interest totaling 8,590,000 shares, an increase of 17.0% from the October 31st total of 7,340,000 shares. Based on an average trading volume of 8,020,000 shares, the days-to-cover ratio is currently 1.1 days.
View Ardelyx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.07. The biopharmaceutical company had revenue of $1.17 million for the quarter, compared to analyst estimates of $0.85 million. Ardelyx had a negative trailing twelve-month return on equity of 171.18% and a negative net margin of 1,266.91%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.06%), Point72 Asset Management L.P. (0.99%), BlackRock Inc. (0.81%), Prosight Management LP (0.60%), Boothbay Fund Management LLC (0.25%) and State Street Corp (0.22%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $1.82.

Ardelyx (NASDAQ:ARDX) has a market capitalization of $341.18 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.